Log in

NASDAQ:CKPTCheckpoint Therapeutics Stock Price, Forecast & News

+0.14 (+7.29 %)
(As of 08/14/2020 04:00 PM ET)
Today's Range
Now: $2.06
50-Day Range
MA: $2.12
52-Week Range
Now: $2.06
Volume325,570 shs
Average Volume415,564 shs
Market Capitalization$113.42 million
P/E RatioN/A
Dividend YieldN/A
Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize the anti-PD-L1 antibodies anti-GITR antibody research programs in the field of hematological malignancies. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
Read More
Checkpoint Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CKPT



Sales & Book Value

Annual Sales$1.71 million
Book Value$0.34 per share


Net Income$-24,710,000.00
Net Margins-1,664.75%


Market Cap$113.42 million
Next Earnings Date11/5/2020 (Estimated)
OptionableNot Optionable
+0.14 (+7.29 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CKPT News and Ratings via Email

Sign-up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions

How has Checkpoint Therapeutics' stock been impacted by COVID-19?

Checkpoint Therapeutics' stock was trading at $1.33 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CKPT shares have increased by 54.9% and is now trading at $2.06.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Checkpoint Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Checkpoint Therapeutics

When is Checkpoint Therapeutics' next earnings date?

Checkpoint Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Checkpoint Therapeutics

How were Checkpoint Therapeutics' earnings last quarter?

Checkpoint Therapeutics Inc (NASDAQ:CKPT) posted its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting the Zacks' consensus estimate of ($0.09). Checkpoint Therapeutics had a negative return on equity of 159.37% and a negative net margin of 1,664.75%.
View Checkpoint Therapeutics' earnings history

What price target have analysts set for CKPT?

3 analysts have issued 12 month price objectives for Checkpoint Therapeutics' stock. Their forecasts range from $8.00 to $20.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $14.33 in the next twelve months. This suggests a possible upside of 595.8% from the stock's current price.
View analysts' price targets for Checkpoint Therapeutics

Has Checkpoint Therapeutics been receiving favorable news coverage?

Media headlines about CKPT stock have been trending neutral this week, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Checkpoint Therapeutics earned a news impact score of 0.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Checkpoint Therapeutics

Are investors shorting Checkpoint Therapeutics?

Checkpoint Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 896,300 shares, an increase of 33.6% from the June 15th total of 670,700 shares. Based on an average trading volume of 289,100 shares, the days-to-cover ratio is presently 3.1 days.
View Checkpoint Therapeutics' Short Interest

Who are some of Checkpoint Therapeutics' key competitors?

What other stocks do shareholders of Checkpoint Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Checkpoint Therapeutics investors own include Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), VBI Vaccines (VBIV) and Corbus Pharmaceuticals (CRBP).

Who are Checkpoint Therapeutics' key executives?

Checkpoint Therapeutics' management team includes the following people:
  • Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
  • Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)

What is Checkpoint Therapeutics' stock symbol?

Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."

Who are Checkpoint Therapeutics' major shareholders?

Checkpoint Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bank of New York Mellon Corp (0.16%), Park Avenue Securities LLC (0.10%), UBS Group AG (0.03%), Commonwealth Equity Services LLC (0.03%) and Virtu Financial LLC (0.03%).
View institutional ownership trends for Checkpoint Therapeutics

Which major investors are selling Checkpoint Therapeutics stock?

CKPT stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG.
View insider buying and selling activity for Checkpoint Therapeutics

Which major investors are buying Checkpoint Therapeutics stock?

CKPT stock was bought by a variety of institutional investors in the last quarter, including Park Avenue Securities LLC, Bank of New York Mellon Corp, Commonwealth Equity Services LLC, and Virtu Financial LLC.
View insider buying and selling activity for Checkpoint Therapeutics

How do I buy shares of Checkpoint Therapeutics?

Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Checkpoint Therapeutics' stock price today?

One share of CKPT stock can currently be purchased for approximately $2.06.

How big of a company is Checkpoint Therapeutics?

Checkpoint Therapeutics has a market capitalization of $113.42 million and generates $1.71 million in revenue each year. The company earns $-24,710,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.

What is Checkpoint Therapeutics' official website?

The official website for Checkpoint Therapeutics is www.checkpointtx.com.

How can I contact Checkpoint Therapeutics?

Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]

This page was last updated on 8/15/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.